Mariappan Chelliah Email & Phone Number

• Extensively contributed to the ongoing development of a drug candidate to treat type-2 diabetes.
• Planned and coordinated animal efficacy studies with an external CRO.
• Designed chemistry experiments and solved problems for chemists working at a CRO firm that Merck was collaborating with.
• Co-invented a best-in-class drug candidate to treat patients infected with hepatitis C virus.
• Made key innovation to improve the pharmacokinetic profile that resulted in the discovery of a best-in-class HCV clinical candidate.

• Inventor of a pre-clinical drug candidate to treat obesity that works by CB1 receptor antagonism.
• Led a technology transfer and played a leadership role collaborating with a CRO and the process group to successfully advance the CB1 program from the lab to pilot scale.
• Played a central role in a collaborative program between Schering-Plough and Mochida Pharmaceuticals (Japan) to discover an anticoagulant drug to treat atrial fibrillation.
• Inventor of pyrimidine analogs as fIXa inhibitors.
• Inventor of cyclic amidine analogs as fIXa inhibitors.

• Recipient of Schering Plough Research Institute’s President Award for innovation and the discovery of Vorapaxar.
• Co-inventor of Vorapaxar, a first-in-class PAR-1 antagonist to treat acute coronary syndrome. Vorapaxar was recently approved by the FDA.
• Solved key enzyme induction, metabolite accumulation and clearance issues shown by the prior development candidates which ultimately led to the discovery of Vorapaxar.
• Inventor of a best-in-class back-up pre-clinical candidate to Vorapaxar.
• Inventor of nor-seco himbacine analogs as potent PAR-1 antagonists.
• Inventor of hetero-himbacine analogs as potent PAR-1 antagonists.

• Contributed to the successful total synthesis of himgaline, a complex alkaloid natural product at Schering-Plough. Chemistry developed in this total synthesis was subsequently applied to the synthesis of constrained.

Phd, Organic Chemistry

Msc, Chemistry

Bsc, Chemistry